Hugh M. Cole, Chief Business Officer at Jounce Therapeutics, Inc. (JNCE), bought 1,900 shares at $7.84 ($15K) on 2018-06-15, disclosed to the SEC on 2018-06-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| JNCE | SELL | 2021-01-25 | $215K | — | Filing → |
| JNCE | SELL | 2021-01-11 | $43K | — | Filing → |
| JNCE | SELL | 2020-08-18 | $10K | — | Filing → |